NCT02706392终止1 期
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Number of Participants That Experienced Adverse Events
研究概览
简要总结
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), stage IV non-small cell lung cancer (NSCLC), or triple negative breast cancer (TNBC) that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Genetically modified therapies, such as ROR1 specific chimeric antigen receptor (CAR) T-cells, are taken from a patient's blood, modified in the laboratory so they specifically may kill cancer cells with a protein called ROR1 on their surfaces, and safely given back to the patient after conventional therapy. The "genetically modified" T-cells have genes added in the laboratory to make them recognize ROR1.
详细描述
PRIMARY OBJECTIVE:
I. To evaluate the safety of adoptive T cell therapy using ex vivo expanded autologous cluster of differentiation (CD)8+ and CD4+ ROR1 CAR-T cells for patients with advanced ROR1+ hematologic (Cohort A) and epithelial (Cohort B) malignancies.
SECONDARY OBJECTIVES:
I. To determine duration of in vivo persistence of adoptively transferred T cells, and the phenotype of persisting T cells.
II. To determine trafficking of adoptively transferred T cells traffic to the bone marrow or other tumor site and function in vivo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL OR ALL (COHORT A)
- •CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody, or who have failed tyrosine kinase or phosphatidylinositol 3 (PI3) kinase inhibitors, or who were not eligible for or declined such therapy; patients with fludarabine refractory disease are eligible
- •Mantle cell lymphoma patients who are beyond first remission and previously treated with chemoimmunotherapy; patients who have relapsed following autologous hematopoietic cell transplant (HCT) are eligible
- •ALL patients who have relapsed or have residual disease following treatment with curative intent; ALL patients must have ROR1 expressed on > 90% of the leukemia blasts to be eligible
- •Confirmation of diagnosis by internal pathology review of initial or subsequent biopsy or other pathologic material at the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA)
- •Evidence of ROR1 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen
- •Karnofsky performance status >= 70%
- •Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
- •Fertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion
- •Ability to understand and provide informed consent
- •INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B):
- •Patients with non-small cell lung cancer that is metastatic or inoperable and who have been treated with at least one line of prior therapy or declined conventional therapy
- •Patients with known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations must have been treated on at least one line of molecularly targeted therapy (e.g., erlotinib, crizotinib)
- •Patients must have measurable disease by at least one of the criteria below:
- •Extra skeletal disease that can be accurately measured in at least one dimension as >= 10 mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- •Skeletal or bone-only disease measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging
- •ROR1 expression in > 20% of the primary tumor or metastasis by immunohistochemistry (IHC)
- •Karnofsky performance status of >= 70%
- •Patients must be off chemotherapy for a minimum of 3 weeks prior to start of treatment; targeted therapies must be stopped at least 3 days prior to start of lymphodepletion
- •Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
- •Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
- •Ability to understand and provide informed consent
- •INCLUSION CRITERIA FOR TNBC:
- •Histologically confirmed diagnosis of metastatic TNBC; i.e. breast cancer that is estrogen receptor (ER) negative (=< 10%), progesterone receptor (PR) negative (=< 10%), and human epidermal growth factor receptor 2 (HER2) negative (0 or 1+ by immunohistochemistry or negative for gene amplification by fluorescence in situ hybridization [FISH])
- •Patients must have measurable disease by at least one of the criteria below:
- •Extra skeletal disease that can be accurately measured in at least one dimension as >= 10 mm with conventional CT techniques as defined by RECIST 1.1
- •Skeletal or bone-only disease measurable by FDG PET imaging
- •Patients must have received standard adjuvant, neoadjuvant, and/or metastatic chemotherapy per National Comprehensive Cancer Network (NCCN) or institutional practice; no maximum on number of prior systemic treatment regimens
- •Patients may receive agents to protect against skeletal related complications such as zoledronic acid or denosumab
- •ROR1 expression in > 20% of the primary tumor or metastasis by IHC
- •Karnofsky performance status of >= 70%
- •Patients must be off chemotherapy for a minimum of 3 weeks prior to planned leukapheresis
- •Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
- •Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
- •Ability to understand and provide informed consent
排除标准
- •EXCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL, OR ALL (COHORT A)
- •Treatment with other investigational agent(s) within 30 days of planned lymphodepletion
- •Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
- •Active autoimmune disease requiring immunosuppressive therapy
- •Serum creatinine > 2.5 mg/dL
- •Serum glutamic oxaloacetic transaminase (SGOT) > 5 x upper limit of normal
- •Bilirubin > 3.0 mg/dL
- •Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in 1 second (FEV1) of =< 65% or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% will be excluded
- •Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an ejection fraction (EF) of 45-49% must receive clearance by a cardiologist to be eligible for the trial
- •Patients who are human immunodeficiency virus (HIV) seropositive
- •Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
- •Women who are breast-feeding
- •Patients who have contraindication to cyclophosphamide chemotherapy
- •Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
- •Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to enrollment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases
- •EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B):
- •Absolute neutrophil count (ANC) < 1000/mm^3
- •Hemoglobin (Hgb) < 9 mg/dl (transfusion permitted to achieve this)
- •Platelet count < 75,000/mm^3
- •Treatment with other investigational agent(s) within 30 days of planned lymphodepletion
- •Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
- •Active autoimmune disease requiring immunosuppressive therapy
- •Serum creatinine > 2.5 mg/dL
- •SGOT > 5 x upper limit of normal
- •Bilirubin > 3.0 mg/dL
- •Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with an FEV1 of =< 65% or DLCO (corrected) < 40% will be excluded
- •Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an EF of 45-49% must receive clearance by a cardiologist to be eligible for the trial
- •Patients who are HIV seropositive
- •Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
- •Women who are breastfeeding
- •Patients who have contraindication to cyclophosphamide chemotherapy
- •Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
- •Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to enrollment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases
- •EXCLUSION CRITERIA FOR TNBC:
- •ANC < 1000/mm^3
- •Hgb < 9 mg/dl (transfusion permitted to achieve this)
- •Platelet count < 75,000/mm^3
- •Treatment with other investigational agent(s) within 30 days of planned lymphodepletion
- •Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
- •Active autoimmune disease requiring immunosuppressive therapy
- •Serum creatinine > 2.5 mg/dL
- •SGOT > 5 x upper limit of normal
- •Bilirubin > 3.0 mg/dL
- •Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with an FEV1 of =< 65% or DLCO (corrected) < 40% will be excluded
- •Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease or a documented ejection fraction of < 45%; any patient with an EF of 45-49% must receive clearance by a cardiologist to be eligible for the trial
- •Patients who are HIV seropositive
- •Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
- •Breast-feeding women
- •Patients who have contraindication to cyclophosphamide chemotherapy
- •Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
- 另有 1 项未显示
结局指标
主要结局
Number of Participants That Experienced Adverse Events
时间窗: Within 35 days of receptor tyrosine kinase-like orphan receptor 1 positive chimeric antigen receptor-T cell infusion
Will be graded according to Common Terminology Criteria for Adverse Events. Outcome will be reported as a count of participants that experienced adverse events in each arm.
次要结局
- Number of Participants Biopsied With Detectable CD3 T-cells(Up to 48 days post infusion)
- Number of Participants With Persistence of Adoptively Transferred Receptor Tyrosine Kinase-like Orphan Receptor 1 Positive Chimeric Antigen Receptor-T Cells(Up to 28 days after the T cell infusion)
- Objective Response Rate of Complete Remission and Partial Remission(Up to 1 year)
- Progression Free Survival(Up to 1 year)
- Overall Survival(Up to 1 year)
研究者
David Maloney
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmAdult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid LeukemiaLate Relapse of Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmInterleukin-3 Receptor Subunit Alpha PositiveRefractory Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMinimal Residual DiseaseNCT02159495City of Hope Medical Center31
已完成
1 期
Vaccine Therapy in Treating Patients With Stage IV Breast CancerHER2-positive Breast CancerRecurrent Breast CancerStage IV Breast CancerMale Breast CancerNCT00791037University of Washington23
进行中（未招募）
1 期
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaMetastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7NCT01955460M.D. Anderson Cancer Center34
进行中（未招募）
1 期
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaAdult Grade III Lymphomatoid GranulomatosisCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaTesticular LymphomaWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT01815749City of Hope Medical Center30
进行中（未招募）
1 期
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant GliomaRecurrent Malignant GliomaRecurrent WHO Grade II GliomaRecurrent WHO Grade III GliomaRefractory GlioblastomaRefractory Malignant GliomaRefractory WHO Grade II GliomaRefractory WHO Grade III GliomaRecurrent GlioblastomaNCT02208362City of Hope Medical Center65